AstraZeneca

November 27, 2024 5:02 PM

Failure of AstraZeneca’s opioid drug trial a major blow for addiction medications: report

The failure of AstraZeneca’s AZD4041 drug trial to combat opioid use disorder (OUD) highlights the challenges in developing non-opioid medications for addiction and withdrawal, according to a report on Wednesday. OUD is a chronic neurological disorder that causes compulsive, repeated use of opioid drugs, leading to prolonged self-administration. The company recently terminated the development of AZD4041 during a Phase II trial, as the orexin 1 receptor antagonist showed a drug-drug interacti...

Thermo Fisher’s plant making infant RSV drug breached FDA rules, documents show

One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years has repeatedly breached rules meant to ensure drugs are free of contamination, FDA documents show, including twice this year. The most recent U.S. Food and Drug Administration inspection of Thermo Fisher's Greenville plant in May identified manufacturing issues for the respiratory syncytial virus drug Beyfortus, a preventive antibody therapy from AstraZeneca and Sanofi for ...